[Development of microencapsulating measles live vaccine].
Designing of non-injection methods of immunization against measles has recently turned into a topical issue. Development of mucosal vaccines ensuring the "entry gate" immunity, which is highly effective in airborne infection, is in the focus of attention. The authors developed a method of microencapsulating the viral particles into the matrix of pH-dependent polymers. Microencapsulated live measles vaccine shaped as 0.6-2.0 microm particles was obtained. The specific activity of measles virus in the drug was 3.36-4.31 log TCD50/0.5 ml. In subcutaneous immunization of guinea pigs with capsules, the best results were obtained in a single administration of vaccine based on ethylcrylate, sodium alginate/ chitosan and sodium slaginate/HMDA. In the intranasal administration of vaccine based on sodium alginate/spermin and sodium alginate/HMDA, there was a need in 2 and 3 stages of immunization.
Nechaeva
E A
EA
Riabicheva
T G
TG
Varaksin
N A
NA
Sen'kina
T Iu
TIu
Zhilina
N V
NV
Smolina
M P
MP
Zaĭtsev
B N
BN
D000180:Acrylic Resins; D000277:Adjuvants, Pharmaceutic; D000281:Administration, Intranasal; D000818:Animals; D002214:Capsules; D002522:Chlorocebus aethiops; D004339:Drug Compounding; D015195:Drug Design; D006168:Guinea Pigs; D007279:Injections, Subcutaneous; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology; D014709:Vero Cells
D000180:Acrylic Resins; D000277:Adjuvants, Pharmaceutic; D002214:Capsules; D008458:Measles Vaccine; C006903:carbopol 940